B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: Results of a randomized controlled trial

Circulation

Volumn 121, Issue 12, 2010, Pages 1432-1438

  Heinz, Judith ^a   Kropf, Siegfried ^b   Domröse, Ute ^b   Westphal, Sabine ^a   Borucki, Katrin ^a   Luley, Claus ^c   Neumann, Klaus H ^b   Dierkes, Jutta ^a  

^a Institute of Clinical Chemistry   (Germany)

^b Division of Nephrology and Hypertension   (Germany)

^c UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

B vitamins; Cardiovascular diseases; Hemodialysis; Homocysteine; Kidney; Mortality; Prevention

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE; VITAMIN B GROUP;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MORTALITY; RENAL DIALYSIS; RISK; TREATMENT FAILURE; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 77950246384     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.904672     Document Type: Article

References (27)

1. Vollset SE, Refsum H, Tverdal A, Nygård O, Nordrehaug JE, Tell GS, Ueland PM. Plasma total homocysteine and cardiovascular and noncar-diovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr. 2001;74:130-136.
2. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057.
3. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
4. Baker F, Picton D, Blackwood S, Hunt J, Erskine M, Dyas M. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation. 2002;106:3642. Abstract.
5. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
6. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, for the NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588.
7. Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygård O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300:795-804.
8. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr, for the Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-1577.
9. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9:S16-S23.
10. Ikizler TA. Epidemiology of vascular disease in renal failure. Blood Purif. 2002;20:6-10.
11. Kundhal K, Lok CE. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract. 2005;101:c47-c52.
12. Dierkes J, Domröse U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000;102:1964-1969.
13. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PW, Selhub J. Hyperhomocys-teinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis. 1995;114:93-103.
14. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2: 386-389.
15. Heinz J, Kropf S, Luley C, Dierkes J. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis. 2009;54:478-489.
16. Sunder-Plassmann G, Födinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, Enzenberger B, Janata O, Winkelmayer WC, Paul G, Auinger M, Barnas U, Hörl WH. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol. 2000;11:1106-1116.
17. Dierkes J, Domröse U, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol. 1999;51: 108-115.
18. Heinz J, Domröse U, Luley C, Westphal S, Kropf S, Neumann KH, Dierkes J. Influence of a supplementation with vitamins on cardiovascular morbidity and mortality in patients with end-stage renal disease: design and baseline data of a randomized clinical trial. Clin Nephrol. 2009;71: 363-365.
19. Dierkes J, Domröse U, Bosselmann KP, Neumann KH, Luley C. Homo-cysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease. J Ren Nutr. 2001;11:67-72.
20. Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem. 1991;29:549-554.
21. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
22. Andersen PK, Gill RD. Cox's regression model counting process: a large sample study. Ann Stat. 1982;10:1100-1120.
23. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191-1194.
24. Frei U, Schober-Halstenberg. Nierenersatztherapie in Deutschland: Bericht über Dialysebehandlung und Nierentransplantation in Deut-schland 2006/2007. QuaSi-Niere gGmbH 2008.
25. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil JJ. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006; 47:1108-1116.
26. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM, for the Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298:1163-1170.
27. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E, for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.